Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine effects in mild Alzheimer's disease: functional MRI study
2006-002182-39Phase 4Completed
- Sponsor
- Hilkka Soininen/Kuopio University Hospital
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Alzheimer's disease (AD) comparing Rivastigmine with Placebo (2 arms). Primary endpoints: Functional MRI response during working memory task and Post-scan recognition memory performance. Started May 2006; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2006-002182-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002182-39.